Related references
Note: Only part of the references are listed.Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops
Manjusha Hurry et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2020)
BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer
Janice S. Kwon et al.
GYNECOLOGIC ONCOLOGY (2019)
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation
Kelly Metcalfe et al.
BRITISH JOURNAL OF CANCER (2019)
A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer
Li Sun et al.
JAMA ONCOLOGY (2019)
Cost-utility analysis of germline BRCA1/2 testing in women with high-grade epithelial ovarian cancer in Spain
Carlota Moya-Alarcon et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2019)
Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer
Dirk Mueller et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2019)
Cost-effectiveness analysis of germ-line BRCA testing in women with breast cancer and cascade testing in family members of mutation carriers
Haitham W. Tuffaha et al.
GENETICS IN MEDICINE (2018)
Valuation of Health and Nonhealth Outcomes from Next-Generation Sequencing: Approaches, Challenges, and Solutions
Dean A. Regier et al.
VALUE IN HEALTH (2018)
BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
Jan Norum et al.
ESMO OPEN (2018)
Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation
Marcelo Cristiano de Azevedo Ramos et al.
REVISTA DE SAUDE PUBLICA (2018)
Personal utility in genomic testing: a systematic literature review
Jennefer N. Kohler et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2017)
A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer
Yonghong Li et al.
VALUE IN HEALTH (2017)
A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer
Anthony Eccleston et al.
VALUE IN HEALTH (2017)
Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
Xavier Ghislain Leon Victor Pouwels et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations
Elvira D'Andrea et al.
GENETICS IN MEDICINE (2016)
County-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research
Beth Woods et al.
VALUE IN HEALTH (2016)
Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium
Christine Fischer et al.
JOURNAL OF MEDICAL GENETICS (2013)
Economic burden of cancer across the European Union: a population-based cost analysis
Ramon Luengo-Fernandez et al.
LANCET ONCOLOGY (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)-Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
Don Husereau et al.
VALUE IN HEALTH (2013)
Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
J. Jaime Caro et al.
VALUE IN HEALTH (2012)
Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
David M. Eddy et al.
VALUE IN HEALTH (2012)
Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality
Susan M. Domchek et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors
Janice S. Kwon et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost-Effectiveness of Testing for Breast Cancer Susceptibility Genes
Margaret L. Holland et al.
VALUE IN HEALTH (2009)
The standard gamble showed better construct validity than the time trade-off
Milo A. Puhan et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2007)
Genetic counseling program in familial breast cancer:: Analysis of its effectiveness, cost and cost-effectiveness ratio
J Balmaña et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Share Paper
